24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
10:24
Meta forced to unmask anonymous Facebook users in defamation lawsuit
10:00
Exit dreams and corporate reality: Untold challenges of Israeli tech acquisitions
09:54
What went wrong at AnyVision? Lessons from a $352M flameout
08:52
2025 is bringing “a search for meaning” among Israelis, inspiring entrepreneurial dreams
More stories
Buzz
Most popular
Daily
Weekly
1
Facial recognition firm Oosto, formerly AnyVision, sold for $125M after raising $352M
2
"Wiz is the world's fastest-growing cyber company and together we can build the largest security company to come out of Israel"
3
Warburg Pincus Signs Deal to Acquire Israeli Credit Card Issuer for $680 Million
4
"Everyone will be a manager" - what the world of work will look like with AI agents
5
Survey finds 50% of high-tech startups in Israel may exhaust funds in six months
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen
Please ensure Javascript is enabled for purposes of
website accessibility